Talaporfin | CAS#110230-98-3 | tumor localizer

MedKoo Cat#: 596920 | Name: Talaporfin free acid

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Talaporfin is an effective tumor localizer that brings about the selective degradation of tumor tissue following light exposure.

Chemical Structure

Talaporfin free acid

CAS#110230-98-3 (free acid)

Theoretical Analysis

MedKoo Cat#: 596920

Name: Talaporfin free acid

CAS#: 110230-98-3 (free acid)

Chemical Formula: C38H43N5O9

Exact Mass: 713.3061

Molecular Weight: 713.78

Elemental Analysis: C, 63.94; H, 6.07; N, 9.81; O, 20.17

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

220201-34-3 (sodium) 110230-98-3 (free acid)

Synonym

Talaporfin; NPe6; Monoaspartyl chlorin; Aspartyl chlorin;

IUPAC/Chemical Name

(3-((1R,4R,5Z,9Z,10Z,14Z,16Z,19Z)-18-carboxy-20-(carboxymethyl)-13-ethyl-3,7,12,17-tetramethyl-8-vinyl-1H,2H,3H,4H-porphyrin-2-yl)propanoyl)-L-aspartic acid

InChi Key

NCUWFASIHRDVKD-IPTASGHTSA-N

InChi Code

InChI=1S/C38H43N5O9/c1-7-20-16(3)24-12-26-18(5)22(9-10-31(44)41-30(37(49)50)15-33(47)48)35(42-26)23(11-32(45)46)36-34(38(51)52)19(6)27(43-36)14-29-21(8-2)17(4)25(40-29)13-28(20)39-24/h7,12-14,18,22,26,30,35,40,42H,1,8-11,15H2,2-6H3,(H,41,44)(H,45,46)(H,47,48)(H,49,50)(H,51,52)/b24-12-,25-13-,29-14-,36-23-/t18?,22?,26-,30-,35+/m0/s1

SMILES Code

O=C(O)C[C@@H](C(O)=O)NC(C/C1=C2[C@@H](CCC(O)=O)[C@H](C)C(/C=C3C(C)=C(C=C)/C(N/3)=C/C(C(C)=C/4CC)=NC4=C/C5=C(C)C(C(O)=O)=C1N5)=N\2)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 713.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Takahashi T, Suzuki S, Misawa S, Akimoto J, Shinoda Y, Fujiwara Y. Photodynamic therapy using talaporfin sodium induces heme oxygenase-1 expression in rat malignant meningioma KMY-J cells. J Toxicol Sci. 2018;43(5):353-358. doi: 10.2131/jts.43.353. PubMed PMID: 29743446. 2: Shimizu K, Nitta M, Komori T, Maruyama T, Yasuda T, Fujii Y, Masamune K, Kawamata T, Maehara T, Muragaki Y. Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. Front Neurol. 2018 Jan 30;9:24. doi: 10.3389/fneur.2018.00024. eCollection 2018. PubMed PMID: 29441040; PubMed Central PMCID: PMC5797572. 3: Fuse T, Tagami T, Tane M, Ozeki T. Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer. Int J Pharm. 2018 Apr 5;540(1-2):50-56. doi: 10.1016/j.ijpharm.2018.01.040. Epub 2018 Feb 2. PubMed PMID: 29410222. 4: Nishie H, Kataoka H, Yano S, Yamaguchi H, Nomoto A, Tanaka M, Kato A, Shimura T, Mizoshita T, Kubota E, Tanida S, Joh T. Excellent antitumor effects for gastrointestinal cancers using photodynamic therapy with a novel glucose conjugated chlorin e6. Biochem Biophys Res Commun. 2018 Feb 19;496(4):1204-1209. doi: 10.1016/j.bbrc.2018.01.171. Epub 2018 Jan 31. PubMed PMID: 29408755. 5: Ikeda H, Ohba S, Egashira K, Asahina I. The effect of photodynamic therapy with talaporfin sodium, a second-generation photosensitizer, on oral squamous cell carcinoma: A series of eight cases. Photodiagnosis Photodyn Ther. 2018 Mar;21:176-180. doi: 10.1016/j.pdpdt.2017.11.016. Epub 2017 Dec 2. PubMed PMID: 29198764. 6: Nakabayashi T, Awasthi K, Ohta N. Application of Fluorescence Lifetime Imaging (FLIM) to Measure Intracellular Environments in a Single Cell. Adv Exp Med Biol. 2017;1035:121-133. doi: 10.1007/978-3-319-67358-5_8. PubMed PMID: 29080134. 7: Hamada R, Ogawa E, Arai T. Oxygen-Enriched Photosensitizer Medium with Red Blood Cells to Study Tissue Interaction of Photosensitization Reaction. Photomed Laser Surg. 2018 Mar;36(3):146-150. doi: 10.1089/pho.2017.4321. Epub 2017 Oct 27. PubMed PMID: 29077539. 8: Kasuya K, Oka K, Soya R, Tsuchiya T, Itoi T, Tsuchida A. Photodynamic therapy for biliary tract organ via a novel ultra-small composite optical fiberscope. Exp Ther Med. 2017 Nov;14(5):4344-4348. doi: 10.3892/etm.2017.5052. Epub 2017 Aug 28. PubMed PMID: 29067113; PubMed Central PMCID: PMC5647730. 9: Ohtani K, Usuda J, Ogawa E, Maehara S, Imai K, Kudo Y, Ono S, Shigefuku S, Eriguchi D, Inoue T, Maeda J, Yoshida K, Hagiwara M, Kakihana M, Kajiwara N, Ohira T, Arai T, Ikeda N. Skin fluorescence following photodynamic therapy with NPe6 photosensitizer. Photodiagnosis Photodyn Ther. 2017 Dec;20:210-214. doi: 10.1016/j.pdpdt.2017.10.001. Epub 2017 Oct 4. PubMed PMID: 28988135. 10: Ogawa E, Arai T. Development of a practical animal model of photodynamic therapy using a high concentration of extracellular talaporfin sodium in interstitial fluid: influence of albumin animal species on myocardial cell photocytotoxicity in vitro. Lasers Med Sci. 2017 Dec;32(9):2105-2109. doi: 10.1007/s10103-017-2324-5. Epub 2017 Oct 5. PubMed PMID: 28980086. 11: Doi M, Ogawa E, Arai T. Effect of a photosensitization reaction performed during the first 3 min after exposure of rat myocardial cells to talaporfin sodium in vitro. Lasers Med Sci. 2017 Nov;32(8):1873-1878. doi: 10.1007/s10103-017-2298-3. Epub 2017 Aug 5. PubMed PMID: 28780623. 12: Tsurubuchi T, Zaboronok A, Yamamoto T, Nakai K, Yoshida F, Shirakawa M, Matsuda M, Matsumura A. Corrigendum to "The optimization of fluorescence imaging of brain tumor tissue differentiated from brain edema-in vivo kinetic study of 5-aminolevulinic acid and talaporfin sodium" [Photodiagn. Photodyn. Ther. 6 (2009), 19-27]. Photodiagnosis Photodyn Ther. 2017 Jun;18:351. doi: 10.1016/j.pdpdt.2016.12.008. Epub 2017 Feb 4. PubMed PMID: 28619661. 13: Kataoka H, Nishie H, Hayashi N, Tanaka M, Nomoto A, Yano S, Joh T. New photodynamic therapy with next-generation photosensitizers. Ann Transl Med. 2017 Apr;5(8):183. doi: 10.21037/atm.2017.03.59. Review. PubMed PMID: 28616398; PubMed Central PMCID: PMC5464935. 14: Ogawa E, Takenoya H, Arai T. Temperature Influence on Myocardial Cell Cytotoxicity of the Extracellular Photosensitization Reaction with Talaporfin Sodium and Serum Proteins at 17°-37°C. Photomed Laser Surg. 2017 Oct;35(10):555-559. doi: 10.1089/pho.2015.4052. Epub 2017 Jun 15. PubMed PMID: 28613976. 15: Nishida T, Takeno S, Nakashima K, Kariya M, Inatsu H, Kitamura K, Nanashima A. Salvage photodynamic therapy accompanied by extended lymphadenectomy for advanced esophageal carcinoma: A case report. Int J Surg Case Rep. 2017;36:155-160. doi: 10.1016/j.ijscr.2017.05.025. Epub 2017 May 26. PubMed PMID: 28587972; PubMed Central PMCID: PMC5459570. 16: Ogawa E, Kurotsu M, Arai T. Irradiance dependence of the conduction block of an in vitro cardiomyocyte wire. Photodiagnosis Photodyn Ther. 2017 Sep;19:93-97. doi: 10.1016/j.pdpdt.2017.05.008. Epub 2017 May 11. PubMed PMID: 28502877. 17: Moy WJ, Yao J, de Feraudy SM, White SM, Salvador J, Kelly KM, Choi B. Histologic changes associated with talaporfin sodium-mediated photodynamic therapy in rat skin. Lasers Surg Med. 2017 Oct;49(8):767-772. doi: 10.1002/lsm.22677. Epub 2017 May 10. PubMed PMID: 28489260; PubMed Central PMCID: PMC5603362. 18: Hong SH, Kim H, Choi Y. Enhanced Fluorescence Imaging and Photodynamic Cancer Therapy Using Hollow Mesoporous Nanocontainers. Chem Asian J. 2017 Jul 18;12(14):1700-1703. doi: 10.1002/asia.201700371. Epub 2017 Jun 8. PubMed PMID: 28463441. 19: Hamada R, Ogawa E, Arai T. Phototoxicity of Vascular Endothelial Cells Caused by Contact with Talaporfin Sodium for 15-120 Min: In Vitro and In Vivo Studies. Photomed Laser Surg. 2017 Jun;35(6):305-310. doi: 10.1089/pho.2016.4164. Epub 2017 Feb 22. PubMed PMID: 28437192. 20: Ishigaki K, Nariai K, Izumi M, Teshima K, Seki M, Edamura K, Takahashi T, Asano K. Endoscopic photodynamic therapy using talaporfin sodium for recurrent intranasal carcinomas after radiotherapy in three dogs. J Small Anim Pract. 2018 Feb;59(2):128-132. doi: 10.1111/jsap.12667. Epub 2017 Mar 31. PubMed PMID: 28369945.